Exact claim · Version 1 · Reviewed 2026-07-23
“Teriparatide reduces fracture risk in defined osteoporosis populations.”
A verdict on this wording and scope, not a universal grade for Teriparatide.
01 · Verdict
Supported with scope
The pivotal evidence and label support vertebral and nonvertebral fracture-risk reduction in studied high-risk populations.
- Evidence basis
- Randomized human outcomes
- Scope
- Labeled osteoporosis populations at high fracture risk.
- Category
- Clinical outcomes
02 · Primary record
Check the attached evidence
01Parathyroid hormone for postmenopausal osteoporosisPubMed · New England Journal of Medicine · Randomized trial · 2001
Supports the scoped claim02FORTEO (teriparatide) prescribing informationU.S. Food and Drug Administration · Drug label · 2024
Supports the scoped claim
Supports the scoped claim02FORTEO (teriparatide) prescribing informationU.S. Food and Drug Administration · Drug label · 2024
Supports the scoped claim
- Editorial review
- Internal editorial review recorded
- Responsible editor
- Anthony Treviso · Founder and responsible editor
- Clinical-review boundary
- Not independently medically reviewed.